Credit Suisse
Credit Suisse is a Swiss financial institution founded in 1856, offering a comprehensive range of banking services through its various divisions. The company operates globally across several segments, including Global Markets, International Wealth Management, Investment Banking, and the Swiss Universal Bank. It specializes in providing over-the-counter derivative products, securities trading, investment research, and advisory services related to mergers and acquisitions, corporate restructuring, and capital raising activities. Credit Suisse also has a private equity arm that focuses on investments in buyouts, venture capital, and mezzanine financing, primarily in Europe and North America. This division invests across various sectors, including clean energy, life sciences, and financial services, typically committing substantial equity capital to middle market firms. Additionally, Credit Suisse is engaged in private equity fund investments and offers specialized services in real estate and structured equity investments. The firm is headquartered in Zurich, Switzerland, and operates various international offices, including significant locations in London and New York.
EZOPS, Inc. is a technology company that specializes in creating machine learning and artificial intelligence software solutions tailored for the financial industry. Founded in 2014 and headquartered in New Brunswick, New Jersey, with additional offices in Ireland, India, and Austria, EZOPS enhances operational efficiency for financial institutions through its ARO platform. This platform offers a suite of features including data aggregation, regulatory reporting, reconciliation, and workflow management, all supported by embedded AI capabilities. The company's solutions focus on data anomaly detection and predictive analytics, providing customizable dashboards and reports that are both user-friendly and asset-class agnostic.
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.